The aim of this study was to evaluate the safety , pharmacokinetics , and clinical response of brodalumab ( AMG 827 ) , a human , anti-IL-17 receptor A ( IL-17RA ) monoclonal antibody in subjects with moderate-to-severe rheumatoid arthritis ( RA ) .